BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors,
chronic kidney disease, and the cardiovascular system and has profound impacts on …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

The American College of Cardiology (ACC) has a long history of develo** documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Abstract The Committee of Clinical Practice Guidelines of the Korean Diabetes Association
(KDA) updated the previous clinical practice guidelines for Korean adults with diabetes and …

A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors
such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for
steatotic liver disease associated with metabolic syndrome. MASLD is the most common …

Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality in
individuals with type 2 diabetes mellitus (T2DM). Secular changes in CVD outcomes have …

Background SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and
kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the …

Cardiovascular-kidney-metabolic (CKM) syndrome is a novel construct recently defined by
the American Heart Association in response to the high prevalence of metabolic and kidney …